# Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

> **NCT02935517** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beacon Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Achromatopsia

## Interventions

- **BIOLOGICAL:** AGTC-402

## Key facts

- **NCT ID:** NCT02935517
- **Lead sponsor:** Beacon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-03
- **Primary completion:** 2022-08
- **Final completion:** 2026-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935517, "Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02935517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*